Our unique process, paired withinnovation and continued improvement and evolution, puts us at the forefront.
Humacyte Closes $75 Million Series C Financing
Humacyte Awarded $3.4 Million Contract Award from The U.S. Department of Defense
Humacyte Receives $14.1 Million Award from California Institute for Regenerative Medicine to Expand Clinical Applications of HUMACYL®
Humacyte Receives Award from the Medical Technology Enterprise Consortium
From lower costs to fewer operations, HAVs may offer critical benefits.
With each year, we’ve movedcloser to lifesaving treatments.